Nucala can now be used in adults for the treatment of a rare autoimmune disease, eosinophilic granulomatosis with polyangiitis, which causes vasculitis, an inflammation in the wall of blood vessels. EGPA, formerly known as Churg Strauss Syndrome, is a condition characterized by asthma, high levels of a type of white blood cell and inflammation in blood vessels.
The FDA first approved Nucala in 2015 to treat patients with severe asthma with an eosinophilic phenotype.
More articles on supply chain:
10 recent pharma layoffs
Sanofi urges Philippine government to lift suspension of its dengue vaccine
Medline to relocate supply distribution center in Maryland, triple its workforce
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
